Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

(2021) Ahsan Wahab et al.   Frontiers in Oncology

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

(2021) Sagar Lonial et al.   CANCER

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

(2021) Malin Hultcrantz et al.   BLOOD

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

(2021) Malin Hultcrantz et al.   BLOOD

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

(2021) Adrian Alegre et al.   BLOOD

Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma

(2021) Tahani Atieh et al.   BLOOD

EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

(2020) Kyriaki Tzogani et al.   ONCOLOGIST

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD